Bamlanivimab as monotherapy for high-risk COVID-19 patients with mild to moderate symptoms

Abstract: ORIGINAL RESEARCH PAPER Volume - 11 | Issue - 07 | July - 2022 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH BAMLANIVIMAB AS MONOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS WITH MILD TO MODERATE SYMPTOMS Emergency Medicine MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, Kathryn Fivelstad STE 203 Las Vegas, NV 89107 USA. Tuong Pham Kristen Meacham Alberto Hazan Patrick Olivieri Michael Doctor * MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MS, Touro University Nevada. 874 American Pacic Drive #8801, Henderson, NV 89014. USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA *Corresponding Author ABSTRACT INTRODUCTION: Coronavirus disease 2019 (COVID-19) is known to progress from mild to severe disease, especially in patients with high-risk comorbidities. Monoclonal antibody treatment of COVID-19 with bamlanivimab has been proposed to decrease illness severity. Non-industry sponsored data is lacking. This study will investigate the effects of bamlanivimab on hospitalization and mortality when administered to patients with COVID-19. METHODS: This was a retrospective analysis of bamlanivimab use within eight emergency departments in Las Vegas, NV. Patients who tested positive for COVID-19 and met inclusion criteria for bamlanivimab but were not administered this treatment were used as a control group. Patients were tracked for hospital admissions and mortality for the 28 days following their treatment. RESULTS: 335 patients diagnosed with COVID-19 were treated with bamlanivimab infusion and tracked for hospitalization within 28 days. Of these patients, 21 (6.3%) required admission, including one who expired on day 46 after a prolonged ICU stay. Of the 148 control patients, 25 required admission (16.9%) and there were no deaths. Relative risk of hospitalization with administration of bamlanivimab was 0.37 (CI 95% 0.22 to 0.61, p<0.01). The absolute risk reduction is 10.6% making the number needed to treat for potential benet 9.4 (95% CI 6.0 to 19.9). CONCLUSION: The results of our study are in alignment with those of the clinical trials funded by Eli Lilly supporting bamlanivimab to reduce 28-day hospitalization for COVID-19 positive patients with mild to moderate symptoms and signicant comorbidities. KEYWORDS COVID-19; Bamlanivimab; Coronavirus; Monoclonal Antibody